Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.
暂无分享,去创建一个
J. Canon | J. Vansteenkiste | P. Vuylsteke | L. Decoster | E. Teugels | J. De Grève | T. Morán | M. Graas | D. Massey | D. Schallier | D. Galdermans | V. Chand